Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by TScan Therapeutics, Inc.

< Previous 1 2 Next >
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics to Participate in Upcoming Investor Conferences
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Transition of Chief Financial Officer
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Closing of Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics to Participate in the Jefferies Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Pricing of $140 Million Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Launch of Proposed Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers AMGN TCRX
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces CEO Transition
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
From TScan Therapeutics, Inc.
Via GlobeNewswire
Tickers TCRX
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.